WO2007071874A3 - Nouveaux composes interagissant avec pea-15 - Google Patents

Nouveaux composes interagissant avec pea-15 Download PDF

Info

Publication number
WO2007071874A3
WO2007071874A3 PCT/FR2006/051367 FR2006051367W WO2007071874A3 WO 2007071874 A3 WO2007071874 A3 WO 2007071874A3 FR 2006051367 W FR2006051367 W FR 2006051367W WO 2007071874 A3 WO2007071874 A3 WO 2007071874A3
Authority
WO
WIPO (PCT)
Prior art keywords
pea
interact
novel compounds
interacting
involve
Prior art date
Application number
PCT/FR2006/051367
Other languages
English (en)
Other versions
WO2007071874A2 (fr
Inventor
Marcel Hibert
Hadjila Chabane
Dominique Bonnet
Jacques Haiech
Francois Renault-Mihara
Herve Chneiweiss
Original Assignee
Inst Nat Sante Rech Med
Marcel Hibert
Hadjila Chabane
Dominique Bonnet
Jacques Haiech
Francois Renault-Mihara
Herve Chneiweiss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Marcel Hibert, Hadjila Chabane, Dominique Bonnet, Jacques Haiech, Francois Renault-Mihara, Herve Chneiweiss filed Critical Inst Nat Sante Rech Med
Priority to EP06842176A priority Critical patent/EP1960420A2/fr
Priority to AU2006328833A priority patent/AU2006328833A1/en
Priority to US12/086,591 priority patent/US20090170749A1/en
Priority to JP2008545064A priority patent/JP2009519305A/ja
Priority to CA002633264A priority patent/CA2633264A1/fr
Publication of WO2007071874A2 publication Critical patent/WO2007071874A2/fr
Publication of WO2007071874A3 publication Critical patent/WO2007071874A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à de nouveaux composés pseudo-peptidiques de formule définie, aptes à interagir avec la protéine PEA- 15 et leur utilisation dans des procédés de criblage et un procédé de diagnostic d'états pathologiques susceptibles d'impliquer PEA-15.
PCT/FR2006/051367 2005-12-16 2006-12-15 Nouveaux composes interagissant avec pea-15 WO2007071874A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06842176A EP1960420A2 (fr) 2005-12-16 2006-12-15 Nouveaux composes interagissant avec pea-15
AU2006328833A AU2006328833A1 (en) 2005-12-16 2006-12-15 Novel compounds which interact with PEA-15
US12/086,591 US20090170749A1 (en) 2005-12-16 2006-12-15 Novel Compounds Which Interact With PEA-15
JP2008545064A JP2009519305A (ja) 2005-12-16 2006-12-15 Ｐｅａ−１５と相互作用する新規化合物
CA002633264A CA2633264A1 (fr) 2005-12-16 2006-12-15 Nouveaux composes interagissant avec pea-15

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0553921 2005-12-16
FR0553921A FR2894963A1 (fr) 2005-12-16 2005-12-16 Nouveaux composes interagissant avec pea-15

Publications (2)

Publication Number Publication Date
WO2007071874A2 WO2007071874A2 (fr) 2007-06-28
WO2007071874A3 true WO2007071874A3 (fr) 2007-08-16

Family

ID=36782537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/051367 WO2007071874A2 (fr) 2005-12-16 2006-12-15 Nouveaux composes interagissant avec pea-15

Country Status (8)

Country Link
US (1) US20090170749A1 (fr)
EP (1) EP1960420A2 (fr)
JP (1) JP2009519305A (fr)
CN (1) CN101336248A (fr)
AU (1) AU2006328833A1 (fr)
CA (1) CA2633264A1 (fr)
FR (1) FR2894963A1 (fr)
WO (1) WO2007071874A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573088T3 (es) 2009-03-27 2016-06-06 Merck Sharp & Dohme Corp. Inhibidores de la replicación del virus de la hepatitis C
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
WO2012003642A1 (fr) * 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Composés tricycliques condensés et leur utilisation pour le traitement de maladies virales
CA2812779A1 (fr) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Derives tetracycliques condenses et procedes d'utilisation de ceux-ci dans le traitement de maladies virales
WO2012122716A1 (fr) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés tétracycliques de xanthène et leurs procédés d'utilisation pour le traitement de maladies virales
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
WO2014110687A1 (fr) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales
EP3059591A1 (fr) * 2015-02-23 2016-08-24 Abivax Procédés de criblage de composés pour traiter ou prévenir une infection virale ou un état associé à un virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189060A1 (fr) * 2000-09-13 2002-03-20 EVOTEC Neurosciences GmbH Procédé de diagnostic pour la maladie d'Alzheimer utilisant la protéine phosphorylée PEA-15
WO2004108961A1 (fr) * 2003-06-06 2004-12-16 Arduini, Arduino Moyens therapeutique et diagnostique contre les papillomes et d'autres maladies impliquant ped/pea-15

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189060A1 (fr) * 2000-09-13 2002-03-20 EVOTEC Neurosciences GmbH Procédé de diagnostic pour la maladie d'Alzheimer utilisant la protéine phosphorylée PEA-15
WO2004108961A1 (fr) * 2003-06-06 2004-12-16 Arduini, Arduino Moyens therapeutique et diagnostique contre les papillomes et d'autres maladies impliquant ped/pea-15

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONDORELLI G ET AL: "PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus.", THE EMBO JOURNAL, vol. 17, no. 14, 15 July 1998 (1998-07-15), pages 3858 - 3866, XP000941497, ISSN: 0261-4189 *
RENAULT F ET AL: "The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes.", BIOCHEMICAL PHARMACOLOGY, vol. 66, no. 8, 15 October 2003 (2003-10-15), pages 1581 - 1588, XP002395277, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
CA2633264A1 (fr) 2007-06-28
EP1960420A2 (fr) 2008-08-27
US20090170749A1 (en) 2009-07-02
JP2009519305A (ja) 2009-05-14
FR2894963A1 (fr) 2007-06-22
AU2006328833A1 (en) 2007-06-28
CN101336248A (zh) 2008-12-31
WO2007071874A2 (fr) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2007071874A3 (fr) Nouveaux composes interagissant avec pea-15
WO2006020269A3 (fr) Biomarqueurs de maladie neurodegenerative
EP1965700A4 (fr) Surveillance d'analyte
WO2007062090A3 (fr) Procedes et compositions lies a des analyses de lymphocytes b
WO2005014850A3 (fr) Systemes et procedes d'analyse de sequences d'acides nucleiques
WO2006089125A3 (fr) Méthodes de détection du cancer de l'ovaire
SG118408A1 (en) Methods of monitoring the concentration of an analyte
IL186918A0 (en) Spectroscopic method for the detection of analytes
EP1931979A4 (fr) Detection microfluidique d'analytes
EP2564864B8 (fr) Méthodes associées au FGF2 pour diagnostiquer et traiter une dépression
GB2469960B (en) Formation tester tool assembly
WO2006113289A3 (fr) Saposine d et fam3c utilises en tant que biomarqueurs de la maladie d'alzheimer
WO2006092610A3 (fr) Marqueurs de melanome
WO2006085121A3 (fr) Biomarqueurs et leurs utilisations
GB0711455D0 (en) Light-sensitive component with increased blue sensitivity, method for the production thereof, and operating method
WO2007106466A3 (fr) Bêta-2 microglobuline utilisée comme biomarqueur pour des maladies artérielles périphériques
EP1901066A4 (fr) Procédé de diagnostic de la maladie d'alzheimer en utilisant une glycoprotéine de sérum comme marqueur biologique
WO2007056288A3 (fr) Methodes d'evaluation de baff
WO2008010837A3 (fr) Immunodosages non compétitifs pour la détection de petites molécules
AP2347A (en) Vehicle monitoring.
IL215528A0 (en) Improved immunoassay methods
EP1807765A4 (fr) Configuration de zone de cvc a auto-diagnostic
EP2102228A4 (fr) Methode de diagnostic de l'eclampsisme
WO2006018259A3 (fr) Procede de detection d'agoniste ou d'antagoniste transporteur de carnitine et utilisations
GB0502065D0 (en) Assay method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008545064

Country of ref document: JP

Ref document number: 2633264

Country of ref document: CA

Ref document number: 2006328833

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006842176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2745/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006328833

Country of ref document: AU

Date of ref document: 20061215

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006328833

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680052412.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006842176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12086591

Country of ref document: US